Infection by SARS-CoV-2 with alternate frequencies of mRNA vaccine boosting

被引:13
|
作者
Townsend, Jeffrey P. [1 ,2 ,3 ,4 ,6 ]
Hassler, Hayley B. [1 ]
Dornburg, Alex [5 ]
机构
[1] Yale Sch Publ Hlth, Dept Biostat, New Haven, CT USA
[2] Yale Univ, Dept Ecol & Evolutionary Biol, New Haven, CT USA
[3] Yale Univ, Program Computat Biol & Bioinformat, New Haven, CT USA
[4] Yale Univ, Program Microbiol, New Haven, CT USA
[5] Univ N Carolina, Dept Bioinformat & Genom, Charlotte, NC USA
[6] Yale Sch Publ Hlth, Dept Biostat, 135 Coll St, New Haven, CT 06510 USA
基金
美国国家科学基金会;
关键词
BNT162b2; mRNA-1273; mRNA vaccines; SARS-CoV-2 variant evolution; updated COVID-19 vaccine; vaccination schedule; ANTIBODY-RESPONSES; DURATION; COVID-19;
D O I
10.1002/jmv.28461
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
One of the most consequential unknowns of the COVID-19 pandemic is the frequency at which vaccine boosting provides sufficient protection from infection. We quantified the statistical likelihood of breakthrough infections over time following different boosting schedules with messenger RNA (mRNA)-1273 (Moderna) and BNT162b2 (Pfizer-BioNTech). We integrated anti-Spike IgG antibody optical densities with profiles of the waning of antibodies and corresponding probabilities of infection associated with coronavirus endemic transmission. Projecting antibody levels over time given boosting every 6 months, 1, 1.5, 2, or 3 years yielded respective probabilities of fending off infection over a 6-year span of >93%, 75%, 55%, 40%, and 24% (mRNA-1273) and >89%, 69%, 49%, 36%, and 23% (BNT162b2). Delaying the administration of updated boosters has bleak repercussions. It increases the probability of individual infection by SARS-CoV-2, and correspondingly, ongoing disease spread, prevalence, morbidity, hospitalization, and mortality. Instituting regular, population-wide booster vaccination updated to predominant variants has the potential to substantially forestall-and with global, widespread uptake, eliminate-COVID-19.
引用
收藏
页数:8
相关论文
共 50 条
  • [41] Cannabidiol and SARS-CoV-2 Infection
    Vallee, Alexandre
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [42] Exosomes and SARS-CoV-2 infection
    Li, Liuying
    Yang, Zixuan
    Li, Jia
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [43] SARS-CoV-2 infection in children
    Cokugras, Haluk
    Onal, Pinar
    TURK PEDIATRI ARSIVI-TURKISH ARCHIVES OF PEDIATRICS, 2020, 55 (02): : 95 - 102
  • [44] Silent battles: immune responses in asymptomatic SARS-CoV-2 infection
    Le Bert, Nina
    Samandari, Taraz
    CELLULAR & MOLECULAR IMMUNOLOGY, 2024, 21 (02) : 159 - 170
  • [45] A Case of Hypophysitis Following Immunization With the mRNA-1273 SARS-CoV-2 Vaccine
    Murvelashvili, Natia
    Tessnow, Alex
    JOURNAL OF INVESTIGATIVE MEDICINE HIGH IMPACT CASE REPORTS, 2021, 9
  • [46] Durability and Cross-Reactivity of SARS-CoV-2 mRNA Vaccine in Adolescent Children
    Burns, Madeleine D.
    Boribong, Brittany P.
    Bartsch, Yannic C.
    Loiselle, Maggie
    St Denis, Kerri J.
    Sheehan, Maegan L.
    Chen, Jessica W.
    Davis, Jameson P.
    Lima, Rosiane
    Edlow, Andrea G.
    Fasano, Alessio
    Balazs, Alejandro B.
    Alter, Galit
    Yonker, Lael M.
    VACCINES, 2022, 10 (04)
  • [47] Longitudinal monitoring of mRNA-vaccine-induced immunity against SARS-CoV-2
    Monzon-Posadas, Werner O.
    Zorn, Jasmin
    Peters, Kathrin
    Baum, Maximilian
    Proksch, Hannah
    Schlueter, Celina Beta
    Menting, Tanja
    Pusnik, Jernej
    Streeck, Hendrik
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [48] Delivery of Experimental mRNA Vaccine Encoding the RBD of SARS-CoV-2 by Jet Injection
    Kisakov, D. N.
    Kisakova, L. A.
    Sharabrin, S. V.
    Yakovlev, V. A.
    Tigeeva, E. V.
    Borgoyakova, M. B.
    Starostina, E. V.
    Zaikovskaya, A. V.
    Rudometov, A. P.
    Rudometova, N. B.
    Karpenko, L. I.
    Ilyichev, A. A.
    BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE, 2024, 176 (06) : 776 - 780
  • [49] Recurring subacute thyroiditis after SARS-CoV-2 mRNA vaccine: A case report
    Vasileiou, Vasiliki
    Paschou, Stavroula A.
    Tzamali, Xakousti
    Mitropoulou, Marina
    Kanouta, Fotini
    Psaltopoulou, Theodora
    Kassi, Georgia N.
    CASE REPORTS IN WOMENS HEALTH, 2022, 33
  • [50] SARS-CoV-2 Infection-and mRNA Vaccine-induced Humoral Immunity among Schoolchildren in Hawassa, Ethiopia
    Merid, Yared
    Tekleselasie, Wondwosen
    Tesfaye, Emnet
    Gadisa, Anteneh
    Fentahun, Dessalegn
    Abate, Alegntaw
    Alemu, Aynalem
    Mihret, Adane
    Mulu, Andargachew
    Gelanew, Tesfaye
    FRONTIERS IN IMMUNOLOGY, 2023, 14